Clinical Trials

46 enrolled

Stomach Neoplasms

NCT07503639 2026-03-31

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

134 enrolled

Locally Advanced Colorectal Cancer

NCT07281768 2026-03-20

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

66 enrolled

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

80 enrolled

Phase 4 Not yet recruiting

Gastric Adenocarcinoma

NCT07446465 2026-03-03

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

42 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07176182 2026-02-27

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

236 enrolled

Phase 2/3 Not yet recruiting

Rectal Neoplasms

NCT07437287 2026-02-27

CROCOBIL

160 enrolled

Biliary Tract Neoplasms

NCT07113275 2026-02-12

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

435 enrolled

Rectal Neoplasms

NCT07383285 2026-02-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

106 enrolled

Rectal Neoplasms Malignant

NCT07381777 2026-02-02

IMMUNOSTAR

270 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT07374250 2026-01-28

Huaxi

154 enrolled

Stomach Neoplasms

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Not yet recruiting

43 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07365592 2026-01-26

Neo-CD

138 enrolled

Colorectal Neoplasms

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

36 enrolled

Phase 4 Not yet recruiting

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT07094893 2026-01-14

ARIEL-ENGIC

280 enrolled

Colorectal Neoplasms

NCT07340567 2026-01-14

CIRCULATEIII

2,450 enrolled

Colorectal Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

30 enrolled

Colorectal Neoplasms

NCT07277842 2025-12-11

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

382 enrolled

Locally Advanced Low Rectal Adenocarcinoma

NCT06783491 2025-11-24

FOXHIPECT4

1,083 enrolled

Colorectal Neoplasms

NCT07243938 2025-11-24

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

70 enrolled

Colorectal Neoplasms

NCT07239466 2025-11-20

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

48 enrolled

Rectal Neoplasms

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT07132008 2025-08-20

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

94 enrolled

Colonic Neoplasms

NCT07118800 2025-08-12

NACRE-2

160 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT07085273 2025-07-31

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

33 enrolled

Stomach Neoplasms

NCT07062536 2025-07-14

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

130 enrolled

Phase 1 Not yet recruiting

Biliary Cancer Metastatic

NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

22 enrolled

Advanced Small Intestine Cancer

NCT07028424 2025-07-01

PANORAMIX

206 enrolled

PDAC - Pancreatic Ductal Adenocarcinoma

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07018063 2025-06-12

YOUNG-NEOS

35 enrolled

Phase 1/2 Not yet recruiting

Neoplasms, Stomach Neoplasms

NCT06990516 2025-05-25

SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer

90 enrolled

Gynecologic

Ovarian Neoplasms

NCT06919510 2025-04-09

A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

90 enrolled

Rectal Neoplasms

NCT06914687 2025-04-06

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

30 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT06899477 2025-03-28

Pre-Operative Treatment in REseCTable COlon CanceR

714 enrolled

Colonic Neoplasms

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

140 enrolled

Stomach Neoplasms

NCT06790212 2025-03-17

Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

168 enrolled

Colonic Neoplasms

NCT06872606 2025-03-12

SCRIPBOT

33 enrolled

Rectal Neoplasms

NCT06751394 2024-12-27

TRACER

44 enrolled

Rectal Neoplasms

NCT06665087 2024-10-30

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

110 enrolled

Phase 2/3 Not yet recruiting

Colonic Neoplasms, Rectal Neoplasms

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

206 enrolled

Biliary Tract Neoplasms

NCT06652412 2024-10-28

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

124 enrolled

Phase NA Not yet recruiting

Colonic Neoplasms, Rectal Neoplasms

NCT06603974 2024-09-19

EASOBFGE

48 enrolled

Stomach Neoplasms

NCT06502080 2024-07-17

RADITOP

128 enrolled

Biliary Tract Neoplasms

NCT06504875 2024-07-17

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Not yet recruiting

23 enrolled

Rectal Neoplasms

NCT06504901 2024-07-17

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

Not yet recruiting

30 enrolled

Phase 4 Not yet recruiting

Colorectal Neoplasms

NCT05498766 2024-06-24

Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients

702 enrolled

Stomach Neoplasms

NCT06447636 2024-06-07

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

20 enrolled

Stomach Neoplasms

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

42 enrolled